Abstract
Background Post-cardiac surgery acute kidney injury (AKI) is common, with high rates of mortality and morbidity. Despite extensive research, the AKI pathogenesis is still unknown. We hypothesised that platelet activation, circulating extracellular vesicles (EV) and micro-RNA levels associate with post-surgery AKI.
Methods Plasma samples were collected from 95 patients recruited to the MaRACAS study before, immediately after and 6-12, 24 and 48 hours after cardiac surgery. Platelet responsiveness was measured with Multiplate. Flow cytometry was used to measure platelet and leukocyte activation and EV derivation, while EV size distribution and concentrations were measured using NanoSight. Circulating soluble biomarkers were measured by immunoassays. Micro-RNA was measured by TaqMan arrays, validated by qPCR.
Results In the 57% (54/95) of patients who developed AKI post-surgery, the numbers of platelet-derived EVs were higher 24 hours after surgery. Platelets in AKI patients were desensitised to ADP 6-12 hours after surgery, independent of the administration of aspirin or P2Y12 antagonists. AKI patients also had more activated platelets 6-12 hours after surgery, more circulating platelet-granulocyte aggregates before and 6-12 and 24 hours after surgery and higher levels of sICAM1 before and 48 hours after surgery. TaqMan arrays identified miR-668 downregulated before and miR-92a-1, –920, –518a-3p, –133b and –1262 upregulated after surgery in AKI patients. qRT-PCR confirmed these differences for miR-1262.
Conclusions AKI is associated with increased platelet activation during cardiac surgery, indicating that alternative platelet inhibition treatments may be renoprotective. Studies in larger cohorts are required to validate these findings.
Competing Interest Statement
All authors have disclosed that they do not have any potential conflicts of interest.
Funding Statement
British Heart Foundation (RG/13/6/29947), (CH/12/1/29419) to GJM, MW, TK, and HA; Leicester and Bristol National Institute for Health Research Cardiovascular Biomedical Research Units.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by East Midlands – Leicester South Research Ethics Committee (REC reference 13/EM/0383)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
1-Changed the title to emphasize the role of platelets 2-Rearranged figures and text to emphasize the role of platelets 3-Removed a co-author (Dr Mustafa Zakkar) upon his request
Data Availability
All data produced in the present work are contained in the manuscript.
